A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

NCT04260256 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped lack of funding

Conditions

Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit

Interventions

DRUG: [18F]F-AraG

Sponsor

CellSight Technologies, Inc.

Collaborators

[object Object]
[object Object]